Background/Aims: To investigate the roles of the oxidative stress related-genes ALOX5, ALOX5AP and MPO in ischemic stroke susceptibility in the Han Chinese population. Methods: A total of 351 ischemic stroke patients and 417 controls were recruited. The ALOX5 rs10900213, ALOX5AP rs4293222 and MPO rs2107545 gene polymorphisms were genotyped. Results: We identified that rs2107545 of MPO gene was significantly associated with ischemic stroke susceptibility after adjusting for covariates. Furthermore, we also considered the likely complexity of oxidative stress and inflammatory process in stroke by assessing the combined effects of multiple genes. Generalized multifactor dimensionality reduction (GMDR) analysis revealed that the combination of ALOX5 rs10900213, ALOX5AP rs4293222 and MPO rs2107545 was significantly associated with increased risk of ischemic stroke (P=0.0040, OR (95% CI) =1.991 (1.241 to 3.195)). Additionally, the MPO rs2107545 genotype was significantly associated with clinical outcomes at 6 months after discharge from the hospital. Conclusion: Our study revealed that epistatic interaction among the ALOX5, ALOX5AP and MPO genes played a significant role in vulnerability to ischemic stroke. Furthermore, these results also suggest that the rs2107545 of MPO gene can be used as a biomarker for the susceptibility and prognosis of ischemic stroke patients.
Introduction
Stroke is the second most common cause of death and a leading cause of long-term disability in adults worldwide. Ischemic stroke, the most common type of stroke, is a complex multifactorial disease caused by the interaction between genetic predisposition and environmental risk factors [1] . Given the complexity and heterogeneous etiology of the disease, the primary pathogenesis of ischemic stroke differs according to race and ethnicity: emboli originating from the heart or extracranial large arteries are common in Western populations, whereas intracranial atherosclerosis, which is associated with lacunae as well as with large infarcts, is more prevalent in the Han Chinese population than in the Western population [2] . A pathogenesis involving atherosclerosis of the brain-feeding arteries is the most common causative mechanism of ischemic stroke in the Han Chinese population [2, 3] . It is imperative to elucidate the underlying genetic architecture of ischemic stroke in the Han Chinese population.
In the past decade, accumulating evidence has shown that oxidative stress burden plays a pivotal role in the process of atherosclerosis [4] . It is believed that oxidative stress level is influenced not only by conventional risk factors, including hypertension and hyperlipidemia [5, 6] , but also by inherited variations in oxidative stress-related genes. Genetic variants, such as single nucleotide polymorphism (SNP) , that have functional effects on oxidative stress pathways may represent unmodifiable, lifelong risk factors, and gene-environment interactions may further contribute to cerebrovascular disease risk [7] . During the past decade, genetic studies have put the spotlight on the association of the leukotriene-generating 5-lipoxygenase (LOX) pathway with atherosclerosis and its clinical manifestations such as myocardial infarction and stroke [8] . Arachidonate 5-lipoxygenase (ALOX5) and its activating protein (ALOX5AP) are critical regulators of leukotriene biosynthesis in the 5-LOX pathway. A genome-wide linkage analysis conducted by the deCODE group in an Icelandic population had suggested a four-SNPs haplotype in the ALOX5AP gene that conferred a nearly doubled risk of stroke in that population [9] . Several groups have attempted to replicate the association between stroke and ALOX5AP variants, but the results have remained controversial [10] [11] [12] [13] [14] [15] . Conversely, although the ALOX5 gene encodes 5-lipoxygenase, the key enzyme of the 5-LOX pathway, and 5-lipoxygenase activity is involved in inflammatory and atherosclerotic processes in the vascular wall, there are few studies focusing on the association between ALOX5 gene polymorphisms and stroke [16] . Additionally, the myeloperoxidase (MPO) gene is another intriguing candidate, as the encoded enzyme catalyzes the formation of MPOderived reactive species that may contribute to the progression of atherosclerosis and the destabilization of atherosclerotic plaques. A study carried out in Portugal presented novel evidence for the involvement of MPO in stroke susceptibility, suggesting a modulation of stroke risk by MPO gene polymorphisms [17] . However, the association between MPO gene and ischemic stroke has not been investigated in the Han Chinese population.
To begin to explore the association between oxidative stress-related genes and ischemic stroke in the Han Chinese population, we identified SNPs in 3 candidate genes that have been previously identified as playing pivotal roles in processes related to oxidative stress (specifically, the genes ALOX5, ALOX5AP and MPO). Since it had been reported in previous studies that the polymorphisms rs4293222 of ALOX5AP, rs10900213 of ALOX5, and rs2107545 of MPO were associated with atherosclerosis-related disease [18, 19] , we chose these three SNPs as genetic markers to explore the association between these oxidative stress-related genes and ischemic stroke. The aim of the study was to explore whether the variants of these oxidative stress genes contribute to the risk of ischemic stroke in the Han Chinese population and further to evaluate the contribution of the interplay of genetic predispositions and conventional risk factors to ischemic stroke risk in order to elucidate the underlying genetic architecture of ischemic stroke. 
Materials and Methods

Recruitment
We consecutively enrolled 670 ischemic stroke patients in the Stroke Unit of the Department of Neurology, the Third Xiangya Hospital of Central South University between June 1 st , 2011, and July 1 st , 2012, and 351 patients who met the inclusion criteria were ultimately included. The diagnosis of stroke was made based on internationally accepted clinical criteria. All patients were recruited within 24 hours after initial stroke symptom onset. In each case, brain CT or MRI imaging was performed on admission. Since a system for categorization of subtypes of ischemic stroke mainly based on etiology had been developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) in 1993, ischemic stroke subtypes are based on the TOAST criterion from that time [20] . The categorization of subtypes of ischemic stroke is according to TOAST criterion in our study. Only patients with Large-artery atherosclerotic (LAA) stroke and mall-artery occlusion (lacunar stroke) were included in this study. Patients with ischemic stroke of cardioembolism (CE), stroke of other determined cause (SOC), stroke of undetermined cause (SUC), recurrent stroke, hemorrhagic stroke, liver or kidney disorders, hematological diseases, chronic inflammatory diseases or tumors of any type were excluded from this study. The following baseline characteristics and risk factors of cerebrovascular disease were recorded: age, gender, hypertension (treated or systolic blood pressure≥ 140 mmHg or diastolic blood pressure≥ 90 mmHg), diabetes (treated or fasting plasma glucose ≥7.0 mmol/L or 2-hour postprandial plasma glucose or random plasma glucose≥11.1 mmol/L). In addition, quantitative traits including weight, body mass index (BMI), blood pressure, fasting blood glucose (FBS) and blood lipids (including TC, TG, LDL-C and HDL-C) were recorded. A group comprising 417 age-and sex-matched healthy individuals were recruited as controls. The control subjects had no history of stroke, hematological diseases, other cerebrovascular disease, liver or kidney disorders, chronic inflammatory diseases, tumors of any type, or pregnancy. This study has been approved by the institutional Medical Ethics Committee at the Third Xiangya Hospital. Informed written consent was acquired from all participants. All experimental procedures were carried out based on the guidelines approved by the Medical Ethics Committee of the Third Xiangya Hospital.
Stroke severity and outcome evaluation
Stroke severity at admission was measured using the National Institutes of Health Stroke Scale (NIHSS; scores ranging from 0 to 42, with higher scores indicating more severe pathology) and the modified Rankin scale (mRS). At 6 months after discharge from the hospital, physical disability was measured with the Barthel Index (BI; scores ranging from 0 to 100). Patients with BI scores equal or less than 85 were classified as having poor recovery; those with BI scores greater than 85 were classified as having good recovery. Functional outcomes were measured using the mRS. Patients with mRS scores of 0-1 were classified in the good recovery group; those with mRS scores of 2-6 were classified in the poor recovery group.
Single-Nucleotide Polymorphism Genotyping
Peripheral venous blood (5 ml) was collected from each of the participants, and genomic DNA was extracted from peripheral blood leukocytes using the phenol-chloroform methods. The genotypes of the SNPs of interest (rs10900213 of the ALOX5 gene, rs4293222 of the ALOX5AP gene and rs2107545 of the MPO gene) were determined using Sequenom iPLEX assays with allele detection by mass spectrometry, Table 1 ). The single-base extension reaction products were separated and evaluated using matrix-assisted laser desorption/ionization time-offlight mass spectrometry (MALDI-TOF-MS) [21] .
Statistical analysis
Statistical analyses were performed using SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL, USA). To identify potential confounders, we performed univariate analyses comparing demographic, clinical and lifestyle risk factors in ischemic stroke patients and controls. An unpaired Student's t-test was used to compare the quantitative data and to determine the differences between the cases and the controls, whereas the chi-squared test or Fisher's exact test was used to compare categorical data. The chi-squared test was also applied to identify deviations from Hardy-Weinberg equilibrium and differences of genotype frequency distribution between ischemic stroke patients and control subjects. Additionally, the differences of genotype frequency distribution in cases and control subjects were analyzed in a stratified analysis by ischemic stroke subtype. Then, logistic regression analyses were performed to verify the effect of the variant on ischemic stroke risk after adjustment for the covariates (diabetes mellitus, hypertension, hyperlipidemia and smoking status). To compare the genotype distribution between patients with good outcome and patients with poor outcome at 6 months, logistic regression analysis was conducted with adjustment for demographic (age and sex) and clinical characteristics (hypertension, diabetes, hyperlipidemia and smoking status). The odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using the allelic genetic model.
To identify higher order gene-gene interactions in our samples, we used the generalized multifactor dimensionality reduction (GMDR) method (GMDR V0.9, http://www.ssg.uab.edu/gmdr). The multifactor dimensionality reduction (MDR) is a nonparametric and genetic model-free machine that outperforms logistic regression for detecting epistatic (gene-gene) interactions. Generalized multifactor dimensionality reduction (GMDR), which is an extension of original MDR, is also called the score-based MDR method. GMDR has three major advantages: (1) it permits adjustment for covariates (2) it provides a unified framework for coherently handling both dichotomous and quantitative phenotypes, and (3) it is applicable to a variety of flexible population-based study designs-for example, it can be applied to detect gene-gene interactions while avoiding "the dimension curse" in case-control studies design. Especially, the GMDR performs better than MDR for ability to permits adjustment for covariates, by introducing the concept of a score statistic into the current MDR framework. The main step is as follow: In the early step, the cumulative score value is calculated within each multifactor cell (each combination) by adjusting covariates. In the later step, each multifactor cell (each combination) is labeled either as "high-risk" if the average score meets or exceeds a preassigned threshold T (e.g., 0) or as "low-risk" if the threshold is not exceeded. Correspondingly, GMDR replace the ratio of cases to controls by the score in each cell (each combination), to evaluate the classification and prediction errors, and thereby identify the best model in later steps. At last, by pooling multilocus genotypes into high-and low-risk groups, the GMDR reduces the dimensionality of the data from N dimensions to one dimension. The new multilocus genotype attribute is then tested for its ability to classify and predict disease status. The GMDR method combines attribute selection, attribute construction, and classification with cross-validation and permutation testing to provide a comprehensive and powerful approach to detecting epistatic effects. It has shown itself to be a useful and efficient statistical tool for detecting gene-gene interactions in case-control studies with relatively small samples size [22, 23] .
We examined gene-gene interactions with the GMDR method to determine which model was the best after adjusting for the covariates (diabetes mellitus, hypertension, hyperlipidemia and smoking status). An exhaustive search of all possible one-locus to three-loci models was performed for all variants. The model with the minimum prediction error, the maximum cross-validation consistency score, and a P value of 0.05 or lower, automatically derived from the sign test by the GMDR software, was considered the best model. This was confirmed by a 1000-permutation test implemented in the GMDR software [22, 23] . Then, we used the software "PS: Power and Sample Size Calculation (PS version 3.0.43)" to calculate statistical power for GMDR analysis. Two-tailed P values <0.05 were considered statistically significant. 
Results
Prevalence risk factors for ischemic stroke
The characteristics of the subjects in our study are summarized in Table 2 . The distributions of age and sex were well matched between cases and controls. Similar distributions were observed in body mass index (BMI) and serum levels of high-density lipoprotein, low-density lipoprotein and triglycerides between the two groups. As expected, significance was noted for total cholesterol, fasting blood glucose (FBS), systolic blood pressure and diastolic blood pressure (P<0.01). Significantly, the stroke group experienced a higher prevalence of smoking status (P <0.01).
Association between specific single-nucleotide polymorphism (SNP) genotypes and risk of ischemic stroke
The genotype frequency distributions for the SNPs and their association with ischemic stroke susceptibility are shown in Table 3 . All of the 3 SNPs tested were in Hardy-Weinberg equilibrium in controls and were thus further analyzed. Rs2107545 of the MPO gene was associated with ischemic stroke susceptibility; with the TT genotype as reference, the presence of the CT genotype was associated with a significantly decreased risk of ischemic stroke after adjustment for hypertension, diabetes, hyperlipidemia and smoking status (adjusted OR=0.583 (0.394-0.861); p=0.007, Table 3 ), the association with ischemic stroke susceptibility remained significant after Bonferroni correction for multiple testing. In contrast, rs4293222 of ALOX5AP showed minimal evidence of association with ischemic stroke because the association did not withstand a Bonferroni correction. Nevertheless, the gene polymorphisms of ALOX5 (rs10900213) did not relate to ischemic stroke susceptibility ( Table 3) . The results of the stratified analysis according to ischemic stroke subtype are Tables 4 and Table 5 . In the logistic analysis according to stratification of ischemic stroke subtype, rs2107545 of MPO was associated with LAA stroke and lacunar stroke (P=0.040, OR (95% CI) =0.813 (0.668 to 0.990) and P=0.041, OR (95% CI) =0.675 (0.462 to 0.985), respectively), whereas rs10900213 of ALOX5 showed a marginal P value with LAA stroke (P=0.050, OR (95% CI) = 0.790 (0.623 to 1.000)), which indicated insufficient evidence for claiming an association ( Table 4 and Table 5 ). Overall, the results highlight a region in the MPO gene as a likely susceptibility locus, with a tag SNP associated with ischemic stroke susceptibility.
Gene polymorphisms, stroke severity at admission, and recovery at 6 months We first analyzed the association between SNP genotypes and stroke severity at admission. After stratification by genotype, we found that all three groups of ischemic stroke patients had similar mean NIHSS (P>0.05) and BI scores (P>0.05), and no significant differences were noted (Table 6 ). A total of 349 ischemic stroke patients were followed up, and their clinical outcome was assessed at 6 months after discharge from the hospital. Of these patients, 98 patients were assigned to the poor recovery group and 251 were assigned to the good recovery group according to the mRS, while 100 patients were assigned to the poor recovery group and 249 were assigned to the good recovery group according to BI scores. With the rs2107545 TT genotype as reference, we found that patients with the rs2107545 CC genotype had significantly poorer outcome at 6 months and a significantly lower prevalence of good recovery as measured by mRS (p=0.006) and BI (p=0.007), whereas the genotypes of other SNPs were not associated with the clinical outcome at 6 months after discharge from the hospital (P>0.05) ( Table 7) . 
Analysis of epistatic (gene-gene) interaction model -results from GMDR analysis
GMDR was used to assess the contribution of combinations of three variants to ischemic stroke, including history of hypertension, diabetes, hyperlipidemia and smoking status as the covariates. Table 8 summarizes the results of the GMDR analysis of ischemic stroke for one to three loci. With adjustments made for covariates, the best combination was the three-loci model (ALOX5 rs10900213, ALOX5AP rs4293222 and MPO rs2107545), which suggested that the three variants together contributed to the etiology of ischemic stroke. The three-loci model had the highest level of testing balance accuracy (0.5512), the cross-validation consistency of 10/10, and scored 9 for the sign test at the 0.0107 level, as shown in Table 8 . Furthermore, the significant interactions between the above three loci models were confirmed by a permutation test implemented in the GMDR software (P=0.032). The three-loci genotype combinations were classified into high-or low-risk groups in GMDR analysis (as shown in Fig. 1 ). In the chi-squared test, the OR value of the high-risk combinations of the synergistic effects model indicated a 1.991-fold increased risk of ischemic stroke (P=0.0040, OR (95% CI)=1.991 (1.241-3.195) ). Then, we used the software "PS: Power and Sample Size Calculation (PS version 3.0.43)" to calculate statistical power of our study. As the OR value is 1.991, the statistical power according to our sample size is nearly 0.996. This result confirmed that the GMDR method is a useful and efficient statistical tool for detecting synergistic interactions while avoiding "the dimension curse," especially for detecting synergistic interactions in case-control studies using relatively small sample sizes.
Overall, the three-loci model (ALOX5AP rs4293222, ALOX5 rs10900213 and MPO rs2107545) had the highest level of testing balance accuracy, cross-validation consistency of 10 and a score of 9 on the sign test (P=0.0107). The three-loci model was thus regarded as the best model of gene-gene interactions. 
Discussion
Identification of genetic main effects and epistatic interactions of oxidative stress-related genes that contribute to ischemic stroke susceptibility in a Han Chinese population
Ischemic stroke is a complex multifactorial disease that is thought to result from interactions between various environmental risk factors and an individual's genetic predisposition [24, 25] . Previous studies revealed that the majority of strokes in the Han Chinese population are of ischemic origin with an atherothrombotic trigger [2, 3] . Our examined stroke patients were composed entirely of LAA and lacunar stroke cases. These two types of ischemic stroke display some prominent overlapping pathogenetic causes [3, 26] , such as hypertension, vascular remodeling (atherosclerosis, microatheroma and lipohyalinosis), and pathological thrombosis. Notably, the underlying vascular remodeling lesions (atherosclerosis, microatheroma and lipohyalinosis) are regarded as lesions with atherosclerotic characteristics, which may be modulated by a common underlying genetic architecture. Accumulating evidence has shown that excessive oxidative stress, which is caused by genetic predisposition and environmental stress, may results in excessive production of reactive oxygen species, inflammation in the arterial atheromatous plaque, unstable atherosclerotic plaque formation and eventually ischemic stroke onset [27] . In this study, we investigated the contribution of epistatic interaction between hypothesized genetic factors involved in oxidative stress pathways to susceptibility of ischemic stroke. Our results revealed a region in the MPO gene as a likely susceptibility locus associated with ischemic stroke risk. Furthermore, our findings suggested for the first time that the epistatic interaction of three genetic variants in ALOX5 (rs10900213), ALOX5AP (rs4293222) and MPO (rs2107545) conferred the genetic susceptibility to ischemic stroke in a Chinese population. We consider the results of the present study to be explorative and thus find the results intriguing. The identification of a synergistic interaction among the ALOX5, ALOX5AP and MPO genes contributing to ischemic stroke susceptibility highlights the importance of testing for epistasis and illustrates the pivotal role of genetic predisposition in ischemic stroke. Moreover, it is also worth mentioning that gene-gene interactions have been reported at the cellular level [28] , which indicates that significant association at the statistical level is relevant to the underlying pathogenesis at the cellular biological level.
The associated genes and potential biological mechanism underlying epistatic interactions
Our study disclosed that epistatic interaction among the ALOX5, ALOX5AP and MPO genes played a pivotal role in vulnerability to ischemic stroke. However, the underlying pathogenetic mechanism of epistasis is hard to interpret according to our current knowledge. It is supposed that various physiological effects of the researched genes in oxidative stress pathways would give a preliminary explanation. ALOX5AP encodes arachidonic 5-LOXactivating protein (FLAP), which is a key component involved in leukotriene biosynthesis within the 5-LOX pathway. Several clinical trials and animal studies in different models suggest beneficial effects of ALOX5AP antagonists in reducing atherosclerosis burden as well as in preventing inflammation and intimal hyperplasia after vessel injury [29] [30] [31] . The ALOX5AP gene is regarded as an important candidate gene for stroke and cardiovascular disease. Since a genome-wide scan identified a four-SNP haplotype within the gene encoding FLAP that predicted a nearly twofold greater risk of stroke [9] , several groups attempted to replicate the association between stroke and ALOX5AP variants, but the results remained controversial [10] [11] [12] [13] [14] [15] . Our previous study revealed that the ALOX5AP gene contributed to stroke risk via epistatic interaction but not genetic main effects [32] . Importantly, a metaanalysis study indicated insufficient evidence for claiming an association between variants in the ALOX5AP gene and risk of stroke, indicating that rigorous genetic association studies investigating gene-gene and gene-environment interactions may generate conclusive findings regarding the contribution of the ALOX5AP gene to stroke [33] . In this study, we focused on the contribution of genes in oxidative stress-related pathways to elucidate the underlying genetic architecture of ischemic stroke in the Han Chinese population. Intriguingly, we identified a synergistic effect of gene-gene interaction between ALOX5AP and other genes, including the ALOX5 and MPO genes. The intriguing results implied that these genes may contribute to ischemic stroke in an epistatic manner through some common underlying pathogenetic mechanism.
The ALOX5 gene encodes 5-lipoxygenase, the key enzyme of the leukotriene-generating 5-LOX pathway. In addition, 5-lipoxygenase activity is required for inflammatory and atherosclerotic responses to oxidized low-density lipoproteins (LDL) in the vascular wall. The expression of 5-lipoxygenase is, in general, limited to leukocytes, such as granulocytes, mast cells, and monocytes, as well as foam cells within atherosclerotic lesions [34] . The first study suggesting an association between the variants within the ALOX5 promoter sequence and atherosclerosis showed increased intima media thickness in healthy carriers of the variant genotype [35] . A recent study revealed that ALOX5 promoter polymorphism is associated with coronary heart disease (CHD) in an Indian population [36] .
accumulating evidence indicates the contribution of ALOX5 promoter polymorphism to atherosclerosis and CHD, there have been fewer studies focused on the association between ALOX5 polymorphism and stroke. A previous report has analyzed the contribution of ALOX5 to stroke, but the association between the single locus of ALOX5 and stroke has not been convincing after correction for multiple testing [16] . Moreover, the results of our singlelocus analysis also indicated insufficient evidence for claiming an association between variants of ALOX5 and stroke. Thus, we postulated that the ALOX5 gene is a low-penetrance susceptibility marker that exerts a minor marginal effect on ischemic stroke, and this gene may impact stroke risk via a synergistic mechanism. Our GMDR analysis confirmed that the three-way combination of ALOX5 (rs10900213), ALOX5AP (rs4293222) and MPO (rs2107545) contributes significantly to the risk of ischemic stroke, which is consistent with previous reports demonstrating that gene-gene interactions in the leukotriene pathway could exert influences on the risk of stroke [16] . Furthermore, our result indicated that the ALOX5 gene contributes to ischemic stroke risk not only by interaction with genetic variants in leukotriene generating 5-LOX pathway but also by interaction with genetic component in other oxidative stress related pathway, such as MPO gene. The revealing finding of GMDR analysis will provide new insights into the genetic architecture of ischemic stroke. It is intriguing that the MPO gene not only modulates susceptibility to ischemic stroke through epistatic interactions but also demonstrates a pivotal main effect independently in our study. The pleiotropic physiological effects of its encoded protein myeloperoxidase (MPO) in oxidative stress pathways and inflammatory cascades would give a preliminary interpretation. Myeloperoxidase is regarded as a pro-oxidant enzyme generated by activated neutrophils and monocytes; it not only modifies LDL particles proatherogenically [37, 38] but also modifies residues on apolipoprotein A1, impairing the conversion of LDL cholesterol to high-density lipoproteins (HDL) [39] . Myeloperoxidase is spatially associated with oxidized LDL and reactive oxygen species (ROS) production in atherosclerotic plaques; it may further contribute to the progression of atherosclerosis and the destabilization of atherosclerotic plaques [40, 41] . Additionally, accumulating evidence indicates that plasma MPO level has the potential to become a useful tool in predicting plaque vulnerability and episodes of cardiovascular events [42, 43] . Thus, MPO is considered an early biomarker of vascular inflammation and a cardiovascular risk factor. Intriguingly, a recent study revealed that a promoter polymorphism (rs2107545) in the MPO gene may affect plasma MPO concentration and contribute to the risk of cardiovascular events through epistatic interaction [19] . In our study, a prominent promoter polymorphism (rs2107545) of MPO was associated with susceptibility to ischemic stroke. Our results are in accordance with a previous study carried out in Portugal, which presented novel evidence for the involvement of MPO in stroke susceptibility [17] . Validation of the association in independent populations is now confirming the moderate effects of MPO gene polymorphism on stroke risk.
Insight into the genetic architecture of ischemic stroke and implications regarding novel strategies for stroke treatment and prevention in the future
It is believed that an allele of a gene cannot define the phenotype of presence or absence of a certain disease without the wider context. This sort of interaction between different loci leading to different phenotypes, called epistasis, is central to our understanding of how a molecular network is coordinated [44] . Given the natural properties of complex networks and the ubiquitous intermolecular dependence in gene regulation and biochemical and metabolic systems, joint actions are the norm rather than the exception in inherited complex traits. The identification of a synergistic interaction among ALOX5, ALOX5AP and MPO contributing to ischemic stroke susceptibility emphasizes the importance of testing for epistasis and illustrates the pivotal role of genetic predisposition in ischemic stroke. Furthermore, our data indicated that stroke susceptibility may be modulated not only by single locus with genetic main effects but also by epistatic (gene-gene) interactions, which is consistent with previous studies. Jia EZ results suggested that the interaction among three loci can engender a significant higher risk than any single locus [45] . In particular, two additional studies also reported that the risk of stroke increases with the number of high-risk genotypes for inflammatory gene polymorphisms, suggesting that epistatic interaction involving multiple loci may change the genetic predisposition of an individual to a disease [17, 46] . Our results indicated that epistasis among ALOX5, ALOX5AP and MPO contributed to ischemic stroke susceptibility. To the best of our knowledge, the epistatic effect of the ALOX5, ALOX5AP and MPO genes may contribute to the crosstalk between inflammatory cascades and oxidative stress pathways and play a vital part in ischemic stroke development. Nevertheless, deep insight, from the statistical level to the biological level, into the essence of the underlying mechanism, will require further investigation. Since oxidative stress and inflammation are closely associated in atherosclerosis, both conditions play significant roles in the pathogenesis of cerebrovascular diseases. First, the leukotrienegenerating 5-LOX pathway is an important inflammatory oxidative stress pathway related to atherosclerosis. Arachidonate 5-lipoxygenase (ALOX5) and its activating protein (ALOX5AP) are critical regulators of leukotriene biosynthesis in the 5-LOX pathway. The leukotrienes are important lipid mediators with immune modulatory and proinflammatory properties. Classical bioactions of leukotrienes include chemotaxis, endothelial adherence, activation of leukocytes, and cytokine production, as well as contraction of smooth muscles in the microcirculation. For example, recent investigations using genetic, morphological, and biochemical approaches have pointed to the involvement of leukotrienes in cardiovascular diseases including atherosclerosis, myocardial infarction and stroke. Several studies either pharmacologically or genetically targeting components of the 5-LOX pathway, such as ALOX5 and ALOX5AP, have indicated both beneficial and neutral effects on atherosclerosis development in animal models [30] [31] [47] [48] [49] . Importantly, a recent phase II randomized, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after acute coronary syndrome did not provide evidence to support a significant anti-inflammatory effect of 5-lipoxygenase inhibition [50] . The complexity of the inflammation cascade may explain the controversy. Inhibition of the 5-LOX pathway may activate other inflammatory pathways, as was observed in human tumor cells, where 5-LOX inhibition activated the cyclooxygenase-2 pathway, and in such cases the beneficial effect of the 5-LOX pathway inhibition will be attenuated [51] . In fact, multiple inflammatory pathways may need to be targeted simultaneously to significantly reduce plaque inflammation and stroke risk.
Meanwhile, our study revealed that the MPO gene modulates susceptibility to ischemic stroke by epistatic interactions and a genetic main effect in our sample. The gene product myeloperoxidase (MPO), which is generated by activated leukocytes (such as neutrophils and monocytes), is a pro-oxidant downstream effecter of the inflammatory cascade. It is well known that the pleiotropic physiological effects of MPO contribute to many oxidative inflammation pathways such as lipoprotein oxidation in atherogenesis, modulating vascular inflammatory responses by regulating NO bioavailability and production of reactive oxygen/ nitrogen species. In particular, MPO-mediated production of reactive oxygen/nitrogen species is regarded as a key mediator of tissue damage in oxidative stress. Evidence from experimental and genetic studies suggests the existence of a potential link between the MPOmediated production of reactive oxygen/nitrogen species and the pathogenesis/progression of atherosclerosis and its serious consequences such as acute myocardial infarction, aortic aneurysms, and stroke. Intriguingly, our results also revealed that the genotype of MPO rs2107545 was significantly associated with clinical outcome at 6 months after discharge from the hospital. The results suggest the potential use of MPO polymorphism as a biomarker for the prognosis of ischemic stroke patients.
The underlying mechanism is unknown but partly attributed to the effects of MPO in the inflammatory oxidative stress process, since inflammation has been shown to correlate with adverse stroke outcomes in animal models and human studies and has been implicated both in propagation of tissue damage and in postischemic tissue repair. Several studies revealed that inhibition of oxidative inflammatory pathway has potent protective effects against ischemia brain injury [52, 53] . Intriguingly, a pharmacological study revealed that MPO is a key mediator of tissue damage and secondary infarct propagation and consolidation in stroke, indicating that MPO is therefore an attractive target for mitigating tissue damage, particularly during the subacute stage of stroke evolution, for which few effective therapies currently exist [54] . However, although MPO is regarded as a link between inflammatory oxidative stress and atherosclerosis, there have been no studies focusing on the effects of MPO inhibition on prevention of atherosclerosis-related disease, such as coronary heart disease and ischemic stroke. Although pharmacotherapy targeting the MPO gene has not been clinically tested for the prevention of cerebrovascular disease, identification of pertinent genes may reveal new therapeutic strategies to counter the influence of gene polymorphisms on oxidative stress, inflammation and atherosclerosis, thereby minimizing its notable vascular complications, such as ischemic stroke.
Conclusion
Our study revealed that epistatic interaction among the ALOX5, ALOX5AP and MPO genes played a significant role in the risk of ischemic stroke in our studied population. Furthermore, it is intriguing that the MPO gene not only modulates susceptibility to ischemic stroke through epistatic interactions but also demonstrates a pivotal genetic main effect in our study. Additionally, the genotype of MPO rs2107545 was significantly associated with clinical outcome at 6 months after discharge from the hospital, which suggests the potential use of MPO polymorphism as a biomarker for the prognosis of ischemic stroke patients. Because of the limited study population, regions, and sample size included in this study, our conclusions require verification using larger sample sizes with additional races and individuals from different geographical regions. Nevertheless, our findings are compatible and strengthen previous genetic and biological observations, highlighting the need for further functional studies, particularly in view of the possible utility of MPO as a prognostic biomarker and a potential drug target for treatment and prevention of ischemic stroke in the future.
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